Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

The UPLC-MS/MS Method for Determination of a Novel Enterovirus 71 Inhibitor in Rat Plasma and its Application to Pharmacokinetic Study

Author(s): Hai-Qiu Ma*, Chen-Qiang Zuo, Ye Yuan, Yu-Pu Zhang, Xue Wang, Shu-Yan Wang and Jun-Wei Liu

Volume 16, Issue 2, 2020

Page: [117 - 124] Pages: 8

DOI: 10.2174/1573412914666180924121855

Price: $65

Abstract

Background: TJAB1099 is a novel, highly active inhibitor of human enterovirus 71 (HEV71), which is a most commonly found virus leading to Hand-Foot-Mouth Disease (HFMD). However, the TJAB1099 could not be detected in the plasma using a regular HPLC-UV detection during the pharmacokinetic study due to the poor solubility, which in turn limited the release prior to be absorbed by the gastrointestinal tract.

Objective: The objectives of the present study were to improve the solubility of TJAB1099 by preparing formulation and develop an Ultra Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS) method applied to the pharmacokinetic study.

Methods: The TJAB1099 was prepared as a phospholipid complex that intends to increase the watersolubility and subsequently improving TJAB1099 exposed in the circulation system. A highly sensitive UPLC-MS/MS method was developed for the pharmacokinetic study, in which the pharmacokinetic parameters were determined following oral and intravenous administration of 5 mg/kg and 1 mg/kg of TJAB1099 in rats, respectively.

Results: The precisions for the method were less than 12.8%, while the accuracies were in the range of 90.8 - 98.0% and 96.1 - 99.6% for within-day and between-day, respectively. The mean recoveries for TJAB1099 and terfenadine (internal-standard, IS) were 85.0 ± 5.4% and 92.4 ± 4.1%, respectively. The pharmacokinetic study revealed that the Cmax of TJAB1099 after oral administration can reach 6.84 ± 2.43 ng/mL, while the Tmax is 0.70 ± 0.11 h. The AUC0-12 is 19.81 ± 11.07 µg/mL/h. However, the absorption was poor with an absolute oral bioavailability of 0.62.

Conclusion: The UPLC-MS/MS method was successfully applied in the pharmacokinetic study of TJAB1099 in rats.

Keywords: Hand-foot-and-mouth disease, UPLC-MS/MS, pharmacokinetics, bioavailability, enterovirus 71, phospholipid complex.

Next »
Graphical Abstract

[1]
McMinn, P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev., 2002, 26(1), 91-107.
[2]
Wang, X.X.; Wei, P.; Ren, J.S.; Hu, Z.Y.; Xu, J.W.; Lou, Z.Y.; Li, X.M.; Yin, W.D.; Shen, X.L.; Porta, C.; Walter, T.S.; Evans, G.; Axford, D.; Owen, R.; Rowlands, D.J.; Wang, J.; Stuart, D.I.; Fry, E.E.; Rao, Z.H. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol., 2012, 19, 424-429.
[3]
Chern, J.H.; Lee, C.C.; Chang, C.S.; Lee, Y.C.; Tai, C.L.; Lin, Y.T.; Shia, K.S.; Lee, C.Y.; Shih, S.R. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg. Med. Chem. Lett., 2004, 14(20), 5051-5056.
[4]
Shang, L.; Wang, Y.; Qing, J.; Shu, B.; Cao, L.; Lou, Z.; Gong, P.; Sun, Y.; Yin, Z. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res., 2014, 112, 47-58.
[5]
De Colibus, L.; Wang, X.; Spyrou, J.A.B.; Kelly, J.; Ren, J.; Grimes, J.; Puerstinger, G.; Stonehouse, N.; Walter, T.S.; Hu, Z.; Wang, J.; Li, X.; Peng, W.; Rowlands, D.; Fry, E.E.; Rao, Z.; Stuart, D.I. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat. Struct. Mol. Biol., 2014, 21(3), 282-288.
[6]
Horwitz, C.; Krut, L.; Kaminsky, L.S. The emulsifying properties of egg yolk phosphatidylcholine. Lipids, 1972, 7(4), 234-239.
[7]
Li, Z.; Vance, D.E. Phosphatidylcholine and choline homeostasis. J. Lipid Res., 2008, 49(6), 1187.
[8]
Us Food and Drug Administration. Guidance for industry bioanalytical method validation; Rockville (MD): US Department of Health and Human Services, CDER and CVM. , 2001.
[9]
Guan, S.; Qin, X.; Zhou, Z. Investigation of the mechanisms of improved oral bioavailability of bergenin using bergenin-phospholipid complex. Drug Dev. Ind. Pharm., 2014, 40(2), 163.
[10]
Lin, D.H.; Wang, C.Z.; Qin, L.F.; Xie, X.X.; Wang, J.T.; Gu, M.; Mcentee, E.; Yuan, C.S. Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. Drug Dev. Ind. Pharm., 2014, 40(2), 186-191.
[11]
Singh, C.; Bhatt, T.D.; Gill, M.S.; Suresh, S. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. Int. J. Pharm., 2014, 460(1-2), 220.
[12]
Murugan, V.; Mukherjee, K.; Maiti, K.; Mukherjee, P.K. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J. Agric. Food Chem., 2009, 57(11), 4559-4565.

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy